Coya Therapeutics Beheer

Naam	Positie	Tenure	Compensatie	Eigendom
Howard Berman	Executive Chair	4.8yrs	US$1.32m	6.24% $ 6.5m
Fred Grossman	President & Chief Medical Officer	1.3yrs	US$862.61k	0% $ 0
David Snyder	CFO & COO	2.7yrs	US$947.89k	0.046% $ 48.0k
Gregory MacMichael	Chief Technical Officer	3yrs	geen gegevens	geen gegevens
Michelle Frazier	Senior Vice President of Regulatory Affairs	1.4yrs	geen gegevens	geen gegevens
Aaron Thome	Head of Neuroinflammation Platform	no data	geen gegevens	geen gegevens
Karen King	Senior VP of Program Management & Clinical Operations	less than a year	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van COYA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Howard Berman	Executive Chair	4.8yrs	US$1.32m	6.24% $ 6.5m
Dov Goldstein	Independent Director	3.7yrs	US$63.75k	0.066% $ 68.5k
Stanley Appel	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lawrence Steinman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Malcolm Brenner	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ann Lee	Independent Director	3.4yrs	US$52.50k	0.15% $ 154.0k
Hideki Garren	Independent Director	3.4yrs	US$55.00k	0.013% $ 13.7k
Merit Cudkowicz	Clinical Advisor	1.3yrs	geen gegevens	geen gegevens
Dieter Weinand	Independent Director	1.3yrs	US$44.16k	geen gegevens
Anabella Villalobos	Independent Director	3.5yrs	US$53.75k	0.066% $ 68.5k
Shimon Sakaguchi	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Clive Svendsen	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van COYA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Coya Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Wilbur Ross Joins Coya Therapeutics' Board

Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors

Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor

Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023

Recent updates

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Coya Therapeutics, Inc. announced that it expects to receive $10.000027 million in funding

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Consensus EPS estimates fall by 10%

New minor risk - Share price stability

Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024

Consensus revenue estimates fall by 24%

Coya Therapeutics, Inc. Submits an Investigational New Drug Application

Consensus revenue estimates fall by 44%

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

New major risk - Shareholder dilution

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

Consensus revenue estimates increase by 64%, EPS downgraded

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Consensus revenue estimates increase by 100%

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral Sclerosis

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Wilbur Ross Joins Coya Therapeutics' Board

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis

New minor risk - Share price stability

Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting

Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled “Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis”

Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors

New major risk - Financial position

Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor

Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023

Coya Therapeutics, Inc. to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Appoints Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs

Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)

Coya Therapeutics, Inc. Announces Appointment of Dr. Guillaume Dorothée to Scientific Advisory Board

Coya Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Coya Therapeutics, Inc. Reports Results from an Open-Label Proof-Of-Concept Clinical Study for COYA 301 in patients with AD. Results of the study

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. has completed an IPO.

High number of new and inexperienced directors

Coya Therapeutics, Inc. has completed an IPO.

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd